Skip to main content

Just Can’t Get Enough of Hydroxychloroquine Several studies on HCQ dosing were presented in the poster and abstract

Social Author Name
Dr. John Cush
Tweet Content
Just Can’t Get Enough of Hydroxychloroquine Several studies on HCQ dosing were presented in the poster and abstract sessions. HCQ has numerous benefits backed by evidence and unless absolutely contraindicated, patients should be maintained on it. Yet... https://t.co/n8drUDDDjh https://t.co/AIoV3s2VhJ

Steroid injections worsen knee arthritis Two studies comparing injections commonly used to relieve the pain of knee os

Social Author Name
Dr. John Cush
Tweet Content
Steroid injections worsen knee arthritis Two studies comparing injections commonly used to relieve the pain of knee osteoarthritis found that corticosteroid injections were associated with the progression of the disease. https://t.co/v7cDBKfM9c https://t.co/sbJ1ro0orW

Low Dose IL-2 Therapy in Sjögren’s There is a large, unmet need in treating Sjögren’s syndrome, yet a new random

Social Author Name
Dr. John Cush
Tweet Content
Low Dose IL-2 Therapy in Sjögren’s There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that lLD-IL-2 was effective and well tolerated in patients with pSS, with evidence of restored immune balance. https://t.co/0obaV0wnGX https://t.co/vgy91cYYvp

Topic Podcasts - Lupus Part1 -A Novel Treatment Response Measurement Tool for Lupus -Breakthrough COVID infection in

Social Author Name
Dr. John Cush
Tweet Content
Topic Podcasts - Lupus Part1 -A Novel Treatment Response Measurement Tool for Lupus -Breakthrough COVID infection in SLE during Omicron era Effect of voclosporin in class V lupus nephritis and more. https://t.co/RVhpZtoo6b https://t.co/jjOZbLZN9m

Pre-RA Pharmacological Interventions: Delaying is not Enough Dr. Aurelie Najm reports on both the Great Debate as well

Social Author Name
Dr. John Cush
Tweet Content
Pre-RA Pharmacological Interventions: Delaying is not Enough Dr. Aurelie Najm reports on both the Great Debate as well as abstracts 0530, 1603 at #ACR22 https://t.co/n8hzJMpmWO https://t.co/8OISSK34No
Rheum Drugs & IDSA Guidelines to Treat COVID-19
The Infectious Diseases Society of America has recently updated its recommendations with regards to the treatment of severely ill, hospitalized COVID-19 infected patients and also about the appropriate use of anti-IL-6, JAKs and colchicine.

The complexity of opioid use in spondyloarthritis A few things we know about opioids: use is common; it’s not effica

Social Author Name
Dr. John Cush
Tweet Content
The complexity of opioid use in spondyloarthritis A few things we know about opioids: use is common; it’s not efficacious in the treatment of spondyloarthritis; and, there is an opioid epidemic and its users are stigmatized. https://t.co/B4Q7Af7doF https://t.co/sdjHoa8shP

ACR22: Polymyalgia Rheumatica in the Spotlight One of the enduring legacies of #ACR22 for Dr. Putman ( @EBRheum) will

Social Author Name
Dr. John Cush
Tweet Content
ACR22: Polymyalgia Rheumatica in the Spotlight One of the enduring legacies of #ACR22 for Dr. Putman ( @EBRheum) will be the emphasis on PMR. Despite being highly inflammatory and relatively common, a remarkable paucity of trials have been run. https://t.co/SYKT3a03Tc https://t.co/9CIRp66vSK

Estimated Global SLE market size was $1.46 billion in 2020, with a global (7 Major countries) prevalence of 651,965 in 2

Social Author Name
Dr. John Cush
Tweet Content
Estimated Global SLE market size was $1.46 billion in 2020, with a global (7 Major countries) prevalence of 651,965 in 2020; and a USA prevalence of 351,176 SLE cases. https://t.co/f4Tghup5PC https://t.co/p1w9KFQR4z
Subscribe to
×